Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL

NCT06890585 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

128

Enrollment

OTHER

Sponsor class

Conditions

BTK Inhibitors
Histone Deacetylase Inhibitor
Double Express Diffuse Large B-cell Lymphoma

Interventions

DRUG: ZCR-CHOP
DRUG: R-CHOP

Sponsor

Li Zhiming